Compare CVS Health Corp (CVS) vs Marvell Technology Inc (MRVL) Price & Performance

CVS Health trades at $95.67, down slightly by 0.03% today. The stock shows strong fundamental momentum with recent quarterly earnings beats, including Q2 2026 EPS of $2.58 versus $1.87 expected, and raised 2026 guidance. Valuation metrics appear reasonable with a P/E of 24.67 and P/S of 0.29. Technical indicators are mixed with a bullish overall signal but bearish moving averages, with key support at $95 and resistance at $96.

The outlook for CVS is positive, supported by earnings strength and analyst consensus, but risks include margin pressure and rising debt levels. The consensus price target of $115.90 implies significant upside, though investors should monitor execution on guidance and healthcare regulatory changes.

Marvell Technology (MRVL) trades at $208.56, down 4.65% on the day, amid a broader semiconductor sell-off. The stock shows a bullish technical signal with support near $201 and resistance at $223. Fundamentally, while recent quarters have seen EPS beats, the company reported a net loss of $885 million for 2025, though revenue grew to $5.77 billion. Analyst sentiment remains strongly positive with an 82% buy rating and a $275.68 consensus price target, citing AI infrastructure growth drivers.

The outlook for MRVL is supported by its positioning in AI data center and optical networking markets, with partnerships like NVIDIA and Microsoft's Maia 300 offering significant upside. Key risks include intense competition, margin pressures, and geopolitical supply chain disruptions. Investors should weigh the high valuation multiples against the potential for AI-driven revenue acceleration in 2026.